RESEARCH-USE BIOSIMILAR ANTIBODY
Opicinumab
Monoclonal antibody · IgG1
Opicinumab (BIIB033) is a human IgG1 monoclonal antibody targeting LINGO-1. Opicinumab binds LINGO-1 to block its negative regulatory signaling, suppress axonal degeneration, enhance axonal regeneration, promote remyelination, and exert neuroprotective effects. Opicinumab maintains axonal protective effects during co-administration with methylprednisolone. Opicinumab can be used for the research of multiple sclerosis, acute optic neuritis, and optic neuritis..
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Opicinumab (BIIB033) is a human IgG1 monoclonal antibody targeting LINGO-1. Opicinumab binds LINGO-1 to block its negative regulatory signaling, suppress axonal degeneration, enhance axonal regeneration, promote remyelination, and exert neuroprotective effects. Opicinumab maintains axonal protective effects during co-administration with methylprednisolone. Opicinumab can be used for the research of multiple sclerosis, acute optic neuritis, and optic neuritis..
Opicinumab is a recombinant research-use antibody directed against LINGO1.